Lay of The Land's conversation today is with Jan Jenson — PhD, CEO/CSO/Founder of Trailhead Biosystems, based here in Cleveland.

Jan is the Lead Inventor of Trailhead Technology and has 20 years as a molecular developmental biologist. He is the Eddie J. Brandon Endowed chair of Diabetes Research at the Cleveland Clinic and obtained his Ph.D. from U. Copenhagen in 1998 and has been faculty at US institutions since 2001 where he has published more than 50 peer-reviewed papers and is now engaged with multiple research projects and consortia covering neural, renal, pancreatic areas, as well as cancer and immunotherapy.

The technology of Trailhead Biosystems — which exists around the high-dimensional design of experiments dependent on computerized designs and robotic executions — allows for the production of cellular ink as the biological building blocks to address a myriad of issues across cell-based therapeutics, drug discovery, organ printing, and disease modeling — ultimately aiming to arrive at the cures for diseases we’ve only historically been able to treat like Diabetes, which is one of Jan’s original motivations.

Trailhead Biosystems is one of the most fascinating companies I’ve come across so far and I learned so much from this conversation with Jan — everything from the basics of cell differentiation and development biology, to the vast implications that unlocking industrialized manufacturing of specialized human cells can have for regenerative medicine! Please enjoy my conversation with Jan Jensen

--

Learn more about Trailhead Biosystems
Connect with Jan Jensen on LinkedIn

--

Connect with Jeffrey Stern on LinkedIn
Follow Jeffrey Stern on Twitter @sternJefe
Follow Lay of The Land on Twitter @podlayoftheland
https://www.jeffreys.page/